April 2, 2021
2 min. read

The Latest in Internal Medicine News: April 2, 2021


This week, we’re sharing the most recent top stories in internal medicine news. This month, a new study showed that the Pfizer covid-19 vaccine holds at least 6 months of protection after the second dose. Two new medications were approved by the FDA to treat severe hypoglycemia and Congenital Heart Disease Complications

Additionally, the National Psoriasis Foundation has new recommendations for those taking the J&J covid-19 vaccine, and more information on a new study of fish consumption and its correlation with lowering major cardiovascular disease (CVD) and mortality risks.

Read more on these stories below:

National Psoriasis Foundation recommends some stop methotrexate for 2 weeks after J&J vaccine MDedge, March 31, 2021

The new guidance states: “Patients 60 or older who have at least one comorbidity associated with an increased risk for poor COVID-19 outcomes, and who are taking methotrexate with well-controlled psoriatic disease, may, in consultation with their prescriber, consider holding it for 2 weeks after receiving theJohnson & Johnson vaccine in order to potentially improve vaccine response.”

partner banner

FDA Approves New Ready-to-Inject Glucagon Product Medscape, March 23, 2021

The US Food and Drug Administration (FDA) has approved dasiglucagon (Zegalogue 0.6 mg/0.6 mL, Zealand Pharma) autoinjector and prefilled syringe for the treatment of severe hypoglycemia in people with diabetes aged 6 and older.

Pfizer COVID-19 Vaccine Protects for 6 Months or More, Study Shows Medscape, March 23, 2021

The Pfizer/BioNTech COVID-19 vaccine affords at least 6 months of protection after the second dose, the companies announced yesterday. The vaccine was 91.3% effective against COVID-19 in an analysis of 927 symptomatic people through March 13. This compares to 95% efficacy reported in the interim results that were announced on November 18, 2020.

FDA Approves First-Ever Device to Treat Congenital Heart Disease Complications HCPLive, March 26, 2021

The US Food and Drug Administration (FDA) has granted breakthrough device designation to Harmony Transcatheter Pulmonary Valve (TPV) System, a first in the world device for the treatment of pediatric and adult patients with congenital heart disease.

Fish Consumption May Lower CV Risk in Patients with Vascular Disease HCPLive, March 10, 2021

A new study has indicated that fish consumption may lower major cardiovascular disease (CVD) and mortality risks in those with a history of vascular disease.

Want to keep updated with Medly? Subscribe to our monthly newsletter!

UTM Source:UTM Campaign:UTM Content:UTM Medium:UTM Term:UTM Device:Landing Page:Company:Last Name:
Join Medly